Hansoh presents Phase 1 HS-20118 data supporting exploration of weekly oral dosing
Company / institutional announcement · Hansoh Pharma
Source published: · Event / reporting date: 2026-05-14
Site published: 2026-11-03 · Updated: 2026-11-03
This source is linked automatically. Choose a question to get started.
What changed
Hansoh presented two randomized, double-blind, placebo-controlled Phase 1 studies of HS-20118 involving 129 treated participants, including healthy volunteers and 23 patients with psoriasis. The company reported sustained pharmacokinetic and pharmacodynamic activity and early skin-response signals supporting exploration of weekly oral dosing. Small patient cohorts and short treatment duration limit conclusions about comparative efficacy and long-term safety.
Why it may matter
Adds early human evidence for oral IL-23R peptides; weekly dosing and durable benefit require larger controlled studies.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections